The global Inhaled Nitric Oxide Delivery Systems market gathered revenue around USD 240.9 Million in 2020 and market is set to grow USD 534.2 Million by the end of 2027 and is estimated to expand at a modest CAGR of 7.9% during the prediction period 2021 to 2027.
The cases of respiratory failure among neonates, increased pollution levels leading to lung diseases in adults, need for quick treatment response, and reduced complications are the factors driving the adoption of inhaled nitric oxide therapy. The presence of several small-scale manufacturers and research initiatives undertaken by major players to prove treatment efficacy against the SARS-CoV-2 virus further enhances market growth.
Safe and effective treatment regimen, a rapid offset of action, reduced toxicity, high concentration of drug at the target organ, avoidance of systemic adverse reaction, and reduced dose of medication are some of the advantages of INO over other medications. This leads to the improved adoption of INO, potentially driving the market growth. Market leaders like Mallinckrodt Pharmaceuticals are providing fundings to conduct clinical trials of INO therapy to treat complications in COVID-19 patients. Such initiatives are said to boost the market growth during the forecasted period.
This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Inhaled Nitric Oxide Delivery Systems market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Inhaled Nitric Oxide Delivery Systems market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.
|Market Size||USD 534.2 Million by 2027|
|Growth Rate||CAGR of 7.9% From 2021 to 2027|
|Forecast Period||2021 to 2027|
|Historic Data||2017 to 2020|
|Report coverage||Growth Factors, Revenue Status, Competitive Landscape, and Future Trends|
|Segments Covered||Type, application, product, end user and Region
|Regional Scope||North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)|
|Companies Mentioned||Mallinckrodt Pharmaceuticals; Getinge; Vero Biotech; LINDE; Beyond Air; SLE; NU MED; Bellerophon Therapeutics; Air Liquide Healthcare; Circassia Pharmaceuticals
COVID-19 Impact Assessment on Market Landscape
The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.
Inhaled Nitric Oxide Delivery Systems market Report empowers readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.
By Type analysis:
The pediatric segment accounted for the largest revenue share of 77.6% in 2020. Inhaled nitric oxide is proved to be the most effective in treating neonatal diseases like Hypoxic Respiratory Failure (HRF). In the U.S. alone, nearly 25,000 to 30,000 neonatal HRF cases are reported annually and nearly 50% are cured using INO therapy. The average cost of this therapy per hour is nearly USD 150, which accounts for a total of USD 97,000 to 130,000 per patient for 72 to 96 hours.
Hence, to fulfill the large medical expense, the government in most countries has established favorable reimbursement policies, which improves the adoption of INO therapy in the neonatal segment. Inhaled nitric oxide needs to be administered in large concentrations in most adult infected diseases and a lack of clinical evidence has led to the reduced adoption of this therapy in the adult segment.
By Application analysis:
Hypoxic Respiratory Failure (HRF) inhaled nitric oxide delivery system held the largest segment share of 80.6% in 2020. This disease is mainly observed in pre-term and near-term neonates due to underlining diseased conditions like pneumonia, sepsis, persistent pulmonary hypertension, and others. It affects 2% of all live births and is responsible for >33% of all neonatal mortality. In the United States, HRF is responsible for the deaths of nearly 18 in 1000 babies, and most of them are born prematurely. Studies suggest that INO is the first line of treatment for HRF and is effectively administered for more than 10 days without the signs of complication.
By Product analysis:
The disposables product segment accounted for the largest revenue share of 65.4% in 2020. On the basis of product, the market is bifurcated into systems and disposables. The presence of a number of manufacturers and increased demand for nebulizer masks in hospitals have led to the increased demand for disposables, thereby driving the segment growth.
Factors, such as the low cost of raw materials, abundant resource availability, and a large consumer base, are also anticipated to boost segment growth. INO delivery devices are priced at USD 1400-1700, which makes it difficult for low-tier end-user settings to adopt such equipment as they focus on minimizing the bills.
By End-user analysis:
The hospitals segment captured the highest revenue share of 86.4% in 2020 owing to the ease of delivery, ability to liquidate for establishing INO delivery device and monitor system, a large number of staff to track device operations, and presence of emergency department. On the basis of end user, the market is segmented into hospitals, surgical centers, and clinics. Mortality rates due to ARFare around 30% in the world. Hence, it is essential to provide these patients with life support and critical care, such as that in hospital ICUs.
North America is expected to be the fastest-growing regional market registering a CAGR of 7.94% during the forecast period. This growth can mainly be attributed to the increasing incidences of neonatal mortality due to the rising cases of HRF. In the United States alone, the annual number of term and late preterm newborns with HRF is estimated at 80,000. And about 15.4% of term infants and 29.7% of late-preterm infants admitted in Neonatal Intensive Care Units(NICU) develop respiratory morbidity.
In addition, a rise in the adoption of INO therapy, favorable government initiative, and the presence of advanced medical infrastructure boosts regional growth. On the other hand, APAC held the largest revenue share in 2020 and will continue the trend during the forecast period due to the growing pediatric population, a rise in the number of patients suffering from respiratory failure, and the presence of local manufacturers of nitric oxide disposables&systems.
Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
Some of the prominent players in the Inhaled Nitric Oxide Delivery Systems Market include: Mallinckrodt Pharmaceuticals; Getinge; Vero Biotech; LINDE; Beyond Air; SLE; NU MED; Bellerophon Therapeutics; Air Liquide Healthcare; Circassia Pharmaceuticals
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2027 and covers subsequent region in its scope:
Middle East & Africa (MEA)
Highlights of the Report:
In the study, a unique research methodology is utilized to conduct extensive research on the growth of the Inhaled Nitric Oxide Delivery Systems market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the Inhaled Nitric Oxide Delivery Systems market study are as follows - statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the market, and makes the projections on the growth prospects of the Inhaled Nitric Oxide Delivery Systems markets more accurate and reliable.
It involves company databases such as Hoover's: This assists us recognize financial information, structure of the market participants and industry competitive landscape.
The secondary research sources referred in the process are as follows:
Primary research includes face-to face interviews, online surveys, and telephonic interviews.
Industry participants involved in this research study include:
Key Points Covered in Inhaled Nitric Oxide Delivery Systems Market Study: